Biocon Limited (IN:BIOCON)

:BIOCON

BIOCON

Biocon Limited

RESEARCH TOOLSreports

Want to see IN:BIOCON full AI Analyst Report?

Biocon Limited (BIOCON) Price & Analysis

16 Followers

BIOCON Stock Chart & Stats

₹364.20

₹0.80(0.22%)

At close: Jan 09 4:00 PM EST

₹364.20

₹0.80(0.22%)

Day’s Range― - ―

52-Week Range₹331.00 - ₹440.30

Previous CloseN/A

Volume1.20M

Average Volume (3M)208.50K

Market Cap

₹670.48B

Enterprise Value₹708.53B

Total Cash (Recent Filing)₹64.69B

Total Debt (Recent Filing)₹165.35B

Price to Earnings (P/E)171.4

Beta0.77

Next Earnings

Aug 06, 2026

EPS Estimate

0.49

Next Dividend Ex-DateN/A

Dividend Yield0.12%

Share Statistics

EPS (TTM)4.01

Shares Outstanding1,620,907,700

10 Day Avg. Volume177,351

30 Day Avg. Volume208,504

Financial Highlights & Ratios

PEG Ratio-1.92

Price to Book (P/B)1.45

Price to Sales (P/S)2.92

P/FCF Ratio-94.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)8.08

Revenue Forecast (FY)₹200.18B

Bulls Say, Bears Say

Bulls Say

Diversified Biopharma ModelBiocon's vertically integrated mix of biosimilars, biologics, APIs and CDMO services creates multiple durable revenue streams and scale benefits. Manufacturing and R&D breadth supports long-term partner deals, supply contracts and risk diversification across therapy areas.

Multi-year Revenue GrowthConsistent top-line expansion indicates sustained market demand and product adoption across segments. Durable revenue growth provides a platform to absorb cyclical pressures, fund R&D and scale biologics production if margins and cash conversion are restored.

Improved Leverage ProfileLower debt-to-equity reduces refinancing and interest-rate risk, improving financial flexibility for long-term investments in capacity and R&D. A healthier capital structure supports strategic partnerships and cushions the firm during cash-cycle recovery.

Bears Say

Sharp Margin CompressionMaterial margin decline erodes the economics of core biologics and API sales, reducing internal funding for R&D and capex. If pricing, mix or cost issues persist, margins could remain impaired for multiple quarters, limiting durable profit recovery.

Negative Free Cash FlowSustained negative free cash flow forces reliance on external financing, partner advances or asset sales to fund operations. This weakens the company's ability to self-finance capacity expansion or long-term R&D, increasing structural funding risk.

Very Low Return On EquityROE near 1% signals poor capital efficiency and limited shareholder value creation. Persistently low ROE suggests structural issues in converting sales into profitable growth, constraining durable reinvestment and dividend capacity.

Biocon Limited News

Biocon Subsidiary Wins Health Canada Nod for Antifungal Micafungin Injection

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Pharma Limited, a subsidiary of Biocon...

1M ago

Biocon Seeks Shareholder Nod for Leadership Changes and Preferential Share Issue via E-Voting

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Limited has initiated a postal ballot...

1M ago

Biocon Reshapes Board and Governance as It Integrates with Biocon Biologics

Biocon Limited ( ($IN:BIOCON) ) has shared an announcement. Biocon’s board approved the audited standalone and consolidated financial...

1M ago

Biocon Delivers Double-Digit Growth in Q4 as Biosimilars Lead Revenue Gains

Biocon Limited ( ($IN:BIOCON) ) has issued an update. Biocon reported consolidated Q4FY26 total income of Rs 4,569...

1M ago

Biocon Clears FY26 Results, Dividend and Board Overhaul to Drive Biologics Integration

Biocon Limited ( ($IN:BIOCON) ) has shared an announcement. Biocon’s board has approved its audited standalone and consolidated...

1M ago

Biocon Files Monitoring Agency Report on QIP Fund Utilisation for March Quarter

Biocon Limited ( ($IN:BIOCON) ) just unveiled an announcement. Biocon Limited has disclosed that India Ratings & Research,...

1M ago

Biocon Denies Leadership Succession Change, Affirms Governance Continuity

Biocon Limited ( ($IN:BIOCON) ) just unveiled an announcement. Biocon Limited has clarified that founder Kiran Mazumdar-Shaw continues...

1M ago

Biocon Plans Investor Meetings in Hong Kong and Singapore

Biocon Limited ( ($IN:BIOCON) ) has shared an announcement. Biocon Limited has scheduled a series of in-person investor...

2M ago

Biocon Overhauls Top Management as It Integrates Biocon Biologics

Biocon Limited ( ($IN:BIOCON) ) just unveiled an announcement. Biocon’s board has approved a significant reshaping of its...

3M ago

Biocon Reshapes Top Management as Biocon Biologics Integration Deepens

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon’s board has approved a major leadership...

3M ago

BIOCON FAQ

What was Biocon Limited’s price range in the past 12 months?

Biocon Limited lowest stock price was ₹331.00 and its highest was ₹440.30 in the past 12 months.

What is Biocon Limited’s market cap?

Biocon Limited’s market cap is ₹670.48B.

When is Biocon Limited’s upcoming earnings report date?

Biocon Limited’s upcoming earnings report date is Aug 06, 2026 which is in 55 days.

How were Biocon Limited’s earnings last quarter?

Biocon Limited released its earnings results on May 07, 2026. The company reported ₹1.27 earnings per share for the quarter, beating the consensus estimate of ₹1.174 by ₹0.096.

Is Biocon Limited overvalued?

According to Wall Street analysts Biocon Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Biocon Limited pay dividends?

Biocon Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.12%. See more information on Biocon Limited dividends here

What is Biocon Limited’s EPS estimate?

Biocon Limited’s EPS estimate is 0.49.

How many shares outstanding does Biocon Limited have?

Biocon Limited has 1,620,907,700 shares outstanding.

What happened to Biocon Limited’s price movement after its last earnings report?

Biocon Limited reported an EPS of ₹1.27 in its last earnings report, beating expectations of ₹1.174. Following the earnings report the stock price went up 0.486%.

Which hedge fund is a major shareholder of Biocon Limited?

Currently, no hedge funds are holding shares in IN:BIOCON

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Biocon Limited

Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.